– SWITZERLAND, Basel – Lyfegen HealthTech AG successfully closes its seed financing round, raising a total of CHF 750’000. The funding was led by Swiss private investors. The funds will be used to further build Lyfegen’s value-based payments platform Lyfevalue and conduct further pilots with partners in the US, Africa, and the EU, including the UK.
“Enabling the shift to sustainable healthcare is a huge challenge, giving us at Lyfegen great purpose and we are honored to work with individuals that truly care about making a difference for patients around the world,” said Girisha Fernando, Lyfegen’s CEO & Founder.
Lyfegen is a healthcare technology company that has developed a ground-breaking solution to accelerate value-based healthcare, entering a market set to grow to USD 390.7 billion by 2024 according to latest market research. Its platform, Lyfevalue, collects, analyses & reconciles disparate healthcare data for the purpose of automating value-based healthcare contracting. The platform enables life sciences companies, national and private healthcare payers and healthcare providers to operationalize value-based healthcare strategies whilst benefiting from a single holistic solution for their value-based healthcare operations. In addition, the platform allows for personalized healthcare by enabling patient level pricing, fostering accelerated and facilitated access to innovative treatments for patients.
Lyfegen HealthTech AG was founded in October 2018 by Girisha Fernando, Michel Mohler, Nico Mros, Leon Rebolledo and James Gannon. After successful careers at F.Hoffmann-La Roche, Novartis AG, and UBS AG, the founders have developed an innovative software solution to overcome technical hurdles in value-based healthcare. Its platform Lyfevalue enables life sciences, healthcare payers and providers to agree on and automatically execute value-based pricing contracts in a trusted, secure & compliant way.
For more information: https://lyfegen.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.